文献速递眼底病与葡萄膜炎

二甲双胍使用与新发ICD编码地图样萎缩之间的关联

The Association Between Metformin Use and New-Onset ICD Coding of Geographic Atrophy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

在Merative MarketScan商业与医疗保险数据库中,2017至2021年间纳入60岁及以上新发ICD编码地图样萎缩(GA)患者进行病例对照研究,按倾向评分匹配无GA对照。全样本中二甲双胍使新发GA的ICD编码几率降低12%(95%CI 0.79-0.99);无糖尿病样本中降低47%(95%CI 0.33-0.83)。作者认为二甲双胍可能作为预防GA发展的非侵入性替代药物,需进一步研究以推动临床试验。

要点

  • 全样本中二甲双胍暴露与新发GA的ICD编码几率降低12%相关(95%CI 0.79-0.99)。
  • 无糖尿病样本中二甲双胍暴露与新发GA的ICD编码几率降低47%相关(95%CI 0.33-0.83)。
  • 作者认为二甲双胍可能作为预防GA发展的非侵入性替代药物,需进一步研究。

核心结论

  • 二甲双胍可能作为预防地图样萎缩(GA)发展的非侵入性替代药物,但需进一步研究以推动临床试验。

研究设计与样本

  • 研究为病例对照研究,纳入2017至2021年Merative MarketScan商业与医疗保险数据库中60岁及以上新发ICD编码GA的患者,按年龄、地区、高血压和Charlson合并症指数估计的倾向评分与同年无GA对照匹配,评估索引就诊前一年的二甲双胍暴露,采用条件多变量logistic回归并调整AMD危险因素计算比值比和95%CI,并在无糖尿病人群中重复该设计与分析。

主要发现

  • 全样本共识别10505例GA病例和10502例匹配的无GA对照,其中1149例(10.9%)病例和1277例(12.2%)对照暴露于二甲双胍,多变量回归中二甲双胍使新发GA的ICD编码几率降低12%(95%CI 0.79-0.99)。
  • 无糖尿病样本共识别7611例GA病例和7608例匹配的无GA对照,其中29例(0.4%)病例和63例(0.8%)对照暴露于二甲双胍,多变量回归中二甲双胍使新发GA的ICD编码几率降低47%(95%CI 0.33-0.83)。

临床怎么用

  • 原文未据此给出推荐,作者在结论中提出二甲双胍可能作为预防GA发展的非侵入性替代药物,并指出需进一步研究以推动临床试验。

局限性

  • 原文指出需要额外研究以进一步探索该发现并推动临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metformin has been suggested to protect against the development of age-related macular degeneration (AMD) in multiple observational studies. However, the association between metformin and geographic atrophy (GA), a debilitating subtype of AMD, has not been analyzed. METHODS: We conducted a case-control study of patients ages 60 years and older with new-onset International Classification of Diseases (ICD) coding of GA in the Merative MarketScan Commercial and Medicare Databases between 2017 and 2021. Cases were matched with propensity scores estimated by age, region, hypertension, and Charlson Comorbidity Index to a control without GA of the same year. Exposure to metformin was assessed for cases and controls in the year prior to their index visit. Conditional multivariable logistic regression, adjusting for AMD risk factors, was used to calculate odd ratios and 95% confidence intervals (CIs). This study design and analysis were repeated in a sample of patients without diabetes. RESULTS: In the full sample, we identified 10,505 cases with GA and 10,502 matched controls without GA. In total, 1149 (10.9%) cases and 1277 (12.2%) controls were exposed to metformin, and in multivariable regression, metformin decreased the odds of new-onset ICD coding of GA by 12% (95% CI, 0.79-0.99). In the sample of patients without diabetes, we identified 7611 cases with GA and 7608 matched controls without GA. Twenty-nine (0.4%) cases and 63 (0.8%) controls were exposed to metformin, and in multivariable regression, metformin decreased the odds of new-onset ICD coding of GA by 47% (95% CI, 0.33-0.83). CONCLUSIONS: Metformin may hold promise as a noninvasive, alternative agent to prevent the development of GA. This finding is notable due to shortcomings in recently approved therapeutics for GA and metformin's overall ease of use and few adverse effects. Additional studies are required to explore our findings further and motivate a clinical trial.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Moir J, Hyman MJ, Gonnah R, et al. The Association Between Metformin Use and New-Onset ICD Coding of Geographic Atrophy. Invest Ophthalmol Vis Sci. 2024. PMID: 38497512. doi:10.1167/iovs.65.3.23

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。